Allogene Therapeutics - ALLO Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALLO shares.
View ALLO analyst ratings or view top-rated stocks.

11 Wall Street research analysts have issued 12-month target prices for Allogene Therapeutics' shares. Their ALLO share price forecasts range from $9.00 to $32.00. On average, they anticipate the company's stock price to reach $20.27 in the next twelve months. This suggests a possible upside of 181.6% from the stock's current price.
View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts.

Allogene Therapeutics' stock was trading at $6.29 at the beginning of 2023. Since then, ALLO shares have increased by 14.5% and is now trading at $7.20.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our ALLO earnings forecast.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its earnings results on Thursday, November, 4th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.01. The business earned $0.05 million during the quarter. Allogene Therapeutics had a negative trailing twelve-month return on equity of 37.74% and a negative net margin of 126,580.16%. During the same period last year, the business earned ($0.52) earnings per share.

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Nordea Investment Management AB (0.45%), Thrivent Financial for Lutherans (0.32%), Coastal Bridge Advisors LLC (0.28%), Swiss National Bank (0.14%), TD Asset Management Inc (0.12%) and Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.11%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends.

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALLO stock can currently be purchased for approximately $7.20.

Allogene Therapeutics (NASDAQ:ALLO) has a market capitalization of $1.04 billion and generates $38.49 million in revenue each year. The company earns $-257,010,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis.

The company employs 308 workers across the globe.

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.allogene.com. The company can be reached via phone at (650) 457-2700 or via email at ir@allogene.com.